Comparative efficacy and safety of TNF-inhibitor plus methotrexate versus oral triple therapy in patients with active rheumatoid arthritis inadequately responding to methotrexate: A meta-analysis of randomized controlled trials

Sang Cheol Bae, Young Ho Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: The study aimed to assess the efficacy and safety of tumor necrosis factor inhibitor (TNFI) with methotrexate (MTX) vs. oral triple therapy in patients with active rheumatoid arthritis (RA), showing inadequate response to MTX. Materials and methods: We performed a meta-analysis of three randomized controlled trials (RCTs) (913 MTX-resistant RA patients) to examine the relative efficacy and safety of TNFI-MTX compared to triple therapy (hydroxychloroquine, sulfasalazine, MTX) in patients with RA responding inadequately to MTX. Results: The American College of Rheumatology's 70% improvement (ACR70) response rate was significantly higher for TNFI-MTX patients than for triple therapy-treated controls (RR 1.549, 95% confidence interval (CI) 1.087 - 2.207, p = 0.016). However, the ACR20 and ACR50 response rates did not differ between the TNFI-MTX group and the triple therapy group. The total Sharp score was significantly lower in TNFI-MTXtreated patients than in triple therapy-treated controls (SMD -0.173, 95% CI -0.301 to -0.045, p = 0.008). There was no significant difference related to the number of patients with serious adverse events between the TNFI-MTX group and the triple therapy group (RR 1.033, 95% CI 0.710 - 1.504, p = 0.864); however, TNFI-MTX resulted in higher infection rates than triple therapy (RR 1.513, 95% CI 1.149 - 1.992, p = 0.004). Conclusion: TNFI-MTX was found to be more effective than triple therapy in active RA patients inadequately responsive to MTX, but it is associated with a higher risk of infection.

Original languageEnglish
Pages (from-to)263-269
Number of pages7
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume56
Issue number6
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Methotrexate
Meta-Analysis
Rheumatoid Arthritis
Randomized Controlled Trials
Safety
Tumor Necrosis Factor-alpha
Therapeutics
Confidence Intervals
Group Psychotherapy
Hydroxychloroquine
Sulfasalazine
Rheumatology
Infection

Keywords

  • Efficacy
  • Rheumatoid arthritis
  • Safety
  • TNFI
  • Triple therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{b88d355dfb3f4f52bbc0310c9cdca060,
title = "Comparative efficacy and safety of TNF-inhibitor plus methotrexate versus oral triple therapy in patients with active rheumatoid arthritis inadequately responding to methotrexate: A meta-analysis of randomized controlled trials",
abstract = "Aims: The study aimed to assess the efficacy and safety of tumor necrosis factor inhibitor (TNFI) with methotrexate (MTX) vs. oral triple therapy in patients with active rheumatoid arthritis (RA), showing inadequate response to MTX. Materials and methods: We performed a meta-analysis of three randomized controlled trials (RCTs) (913 MTX-resistant RA patients) to examine the relative efficacy and safety of TNFI-MTX compared to triple therapy (hydroxychloroquine, sulfasalazine, MTX) in patients with RA responding inadequately to MTX. Results: The American College of Rheumatology's 70{\%} improvement (ACR70) response rate was significantly higher for TNFI-MTX patients than for triple therapy-treated controls (RR 1.549, 95{\%} confidence interval (CI) 1.087 - 2.207, p = 0.016). However, the ACR20 and ACR50 response rates did not differ between the TNFI-MTX group and the triple therapy group. The total Sharp score was significantly lower in TNFI-MTXtreated patients than in triple therapy-treated controls (SMD -0.173, 95{\%} CI -0.301 to -0.045, p = 0.008). There was no significant difference related to the number of patients with serious adverse events between the TNFI-MTX group and the triple therapy group (RR 1.033, 95{\%} CI 0.710 - 1.504, p = 0.864); however, TNFI-MTX resulted in higher infection rates than triple therapy (RR 1.513, 95{\%} CI 1.149 - 1.992, p = 0.004). Conclusion: TNFI-MTX was found to be more effective than triple therapy in active RA patients inadequately responsive to MTX, but it is associated with a higher risk of infection.",
keywords = "Efficacy, Rheumatoid arthritis, Safety, TNFI, Triple therapy",
author = "Bae, {Sang Cheol} and Lee, {Young Ho}",
year = "2018",
month = "1",
day = "1",
doi = "10.5414/CP203202",
language = "English",
volume = "56",
pages = "263--269",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "6",

}

TY - JOUR

T1 - Comparative efficacy and safety of TNF-inhibitor plus methotrexate versus oral triple therapy in patients with active rheumatoid arthritis inadequately responding to methotrexate

T2 - A meta-analysis of randomized controlled trials

AU - Bae, Sang Cheol

AU - Lee, Young Ho

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: The study aimed to assess the efficacy and safety of tumor necrosis factor inhibitor (TNFI) with methotrexate (MTX) vs. oral triple therapy in patients with active rheumatoid arthritis (RA), showing inadequate response to MTX. Materials and methods: We performed a meta-analysis of three randomized controlled trials (RCTs) (913 MTX-resistant RA patients) to examine the relative efficacy and safety of TNFI-MTX compared to triple therapy (hydroxychloroquine, sulfasalazine, MTX) in patients with RA responding inadequately to MTX. Results: The American College of Rheumatology's 70% improvement (ACR70) response rate was significantly higher for TNFI-MTX patients than for triple therapy-treated controls (RR 1.549, 95% confidence interval (CI) 1.087 - 2.207, p = 0.016). However, the ACR20 and ACR50 response rates did not differ between the TNFI-MTX group and the triple therapy group. The total Sharp score was significantly lower in TNFI-MTXtreated patients than in triple therapy-treated controls (SMD -0.173, 95% CI -0.301 to -0.045, p = 0.008). There was no significant difference related to the number of patients with serious adverse events between the TNFI-MTX group and the triple therapy group (RR 1.033, 95% CI 0.710 - 1.504, p = 0.864); however, TNFI-MTX resulted in higher infection rates than triple therapy (RR 1.513, 95% CI 1.149 - 1.992, p = 0.004). Conclusion: TNFI-MTX was found to be more effective than triple therapy in active RA patients inadequately responsive to MTX, but it is associated with a higher risk of infection.

AB - Aims: The study aimed to assess the efficacy and safety of tumor necrosis factor inhibitor (TNFI) with methotrexate (MTX) vs. oral triple therapy in patients with active rheumatoid arthritis (RA), showing inadequate response to MTX. Materials and methods: We performed a meta-analysis of three randomized controlled trials (RCTs) (913 MTX-resistant RA patients) to examine the relative efficacy and safety of TNFI-MTX compared to triple therapy (hydroxychloroquine, sulfasalazine, MTX) in patients with RA responding inadequately to MTX. Results: The American College of Rheumatology's 70% improvement (ACR70) response rate was significantly higher for TNFI-MTX patients than for triple therapy-treated controls (RR 1.549, 95% confidence interval (CI) 1.087 - 2.207, p = 0.016). However, the ACR20 and ACR50 response rates did not differ between the TNFI-MTX group and the triple therapy group. The total Sharp score was significantly lower in TNFI-MTXtreated patients than in triple therapy-treated controls (SMD -0.173, 95% CI -0.301 to -0.045, p = 0.008). There was no significant difference related to the number of patients with serious adverse events between the TNFI-MTX group and the triple therapy group (RR 1.033, 95% CI 0.710 - 1.504, p = 0.864); however, TNFI-MTX resulted in higher infection rates than triple therapy (RR 1.513, 95% CI 1.149 - 1.992, p = 0.004). Conclusion: TNFI-MTX was found to be more effective than triple therapy in active RA patients inadequately responsive to MTX, but it is associated with a higher risk of infection.

KW - Efficacy

KW - Rheumatoid arthritis

KW - Safety

KW - TNFI

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=85048045121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048045121&partnerID=8YFLogxK

U2 - 10.5414/CP203202

DO - 10.5414/CP203202

M3 - Article

C2 - 29578394

AN - SCOPUS:85048045121

VL - 56

SP - 263

EP - 269

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 6

ER -